Marker Therapeutics, Inc. (MRKR) Stock: Here’s What’s Happening


Marker Therapeutics, Inc. (MRKR) is making a move up in the market today. The company, one that is focused on the biotech sector, is currently trading at $4.64 after climbing 4.04% so far today. As it relates to biotechnology companies, there are quite a few factors that have the ability to cause movement in the market. One of the most common is news. Here are the most recent trending headlines relating to MRKR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 04:01PM Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results
12:04PM Do Insiders Own Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Aug-06-19 04:05PM Marker Therapeutics Appoints Steve Elms to its Board of Directors
Jul-20-19 11:00AM Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR
Jul-17-19 07:00AM Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma

Nonetheless, any time investors are making a decision to invest, prospective investors should look at far more than news, especially in the generally speculative biotechnology sector. Here’s what’s going on with Marker Therapeutics, Inc..

Performance Trends That We’ve Seen From MRKR

While a move toward the top in a single session, like what we’re seeing from Marker Therapeutics, Inc. might make some investors happy, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally important to dig into trends experienced by the stock for a period longer than a single trading session. In the case of MRKR, below are the returns that investors have seen:

  • Weekly – Throughout the past seven days, MRKR has seen a change in value amounting to 3.72%.
  • Monthly – The ROI from Marker Therapeutics, Inc. throughout the last month comes to -47.84%.
  • Past Three Months – Over the past 3 months, the company has produced a ROI that comes to -20.07%
  • Past Six Months – Throughout the previous six months, we’ve seen a performance that works out to -12.55% from the stock.
  • This Year So Far – Since the the first trading session of this year MRKR has produced a return of -19.64%.
  • Full Year – Finally, in the last year, investors have seen a change in the amount of -41.01% out of MRKR. Over this period, the stock has sold at a high of -56.23% and a low of 16.88%.

Ratios Worth Watching

Digging into a few key ratios having to do with a stock can give prospective investors a look of just how dangerous and/or rewarding a pick may be. Below are a few of the most important ratios to look at when looking at MRKR.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the stock is headed for declines. Across the sector, biotech stocks tend to come with a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, as it relates to Marker Therapeutics, Inc., it’s short ratio clocks in at 8.05.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure If a company is able to pay its debts when they mature based on current assets or quick assets. In the biotech sector, many companies rely on the continuation of investor support, the quick and current ratios can be bad. Nonetheless, several gems in the biotechnology industry do have positive current and quick ratios. As far as MRKR, the quick and current ratios come to 19.70 and 19.70 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. In the case of Marker Therapeutics, Inc., the book to share value ratio is 1.22.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to think about. As it relates to MRKR, the cash to share value works out to 1.26.

What Analysts Say About Marker Therapeutics, Inc.

While it’s never a good idea to blindly follow the opinions of analysts, it is a good idea to consider their thoughts when validating your own opinions before making an investment decision in the biotechnology industry. Below are the most recent moves that we’ve seen from analysts when it comes to MRKR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-30-19 Initiated ROTH Capital Buy
Mar-01-19 Initiated Janney Buy
Dec-03-18 Upgrade Piper Jaffray Neutral → Overweight

Investors Tend To Follow The Big Money

One thing I have come to understand so far in my short time on Earth has been that smart investors tend to follow big money players. In other words, investors that want to keep their investments relatively safe will watch moves made by institutional investors and insiders. So, is big money interested as it relates to MRKR? Here’s what’s going on:

Institutions own 35.50% of the company. Institutional interest has moved by 1.68% over the past three months. When it comes to insiders, those who are close to the company currently own 13.50% percent of MRKR shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

A Look At Share Counts

Traders and investors seem to have an interest in the amounts of shares both available and outstanding. In terms of Marker Therapeutics, Inc., currently there are 45.92M with a float of 30.96M. These data mean that out of the total of 45.92M shares of MRKR in existence today, 30.96M are able to trade hands in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to MRKR, the short percent of the float is 17.86%.

What We’ve Seen In earnings results

What have ween seen from MRKR in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – Currently, Wall St. analysts are expecting that Marker Therapeutics, Inc. will generate EPS in the amount of -0.52, with -0.13 being reported in the report for the current quarter. Although this is not associated with earnings, because we’re chatting on the topic of Wall St. analysts, MRKR is currently graded as a 1.70 on a scale from 1 to 5 where 1 is the worst possible Wall St. analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past half decade, Marker Therapeutics, Inc. has reported a change in sales that works out to be 0. Earnings over the past 5 years have experienced movement in the amount of 33.20%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often referred to as in today’s society, the company has generated a change in earnings in the amount of 61.10%. The company has also seen a change in regard to sales volume that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, based on what I am, I can learn by myself. However, I was created by a human and human beings actually play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at something? If so, write a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here